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Introduction {#sec005}
============

HIV-1 remains a global health problem of unparalleled magnitude, with an estimated 36.9 million people living with HIV in 2017 \[[@pone.0238027.ref001]\]. The pandemic is dynamic, with 1.8 million new infections each year. An estimated 3.2 million Nigerians are currently estimated to be living with HIV, making it the second largest epidemic worldwide \[[@pone.0238027.ref002]\].

HIV-1 is a highly diverse virus due to significant genetic variability. It is classified into four groups: M (major), group O (outlier), group N (nonmajor nonoutlier), and P \[[@pone.0238027.ref003], [@pone.0238027.ref004]\]. HIV-1 group M is the most prevalent circulating group, has nine subtypes (designated A to D, F to H, and J and K), numerous circulating recombinant forms (CRFs) and multiple unique recombinant forms (URFs) \[[@pone.0238027.ref004], [@pone.0238027.ref005]\].

The distribution of HIV-1 subtypes and recombinants across the world varies and this regional diversity may have clinical implications. CRF02_AG is the fourth most prevalent subtype globally, together with subtype G remain the dominant variants observed in West Africa \[[@pone.0238027.ref006]\]. In Nigeria, subtypes A, B, C, D, F2, G, J, and group O have been identified along with several CRFs in varying proportions \[[@pone.0238027.ref007]--[@pone.0238027.ref010]\]. The distribution of HIV-1 variants in Nigeria seems to differ based on geography, as subtype G is most prevalent in the north and CRF02_AG in the south \[[@pone.0238027.ref008], [@pone.0238027.ref011]\].

There are significant sequence differences in the structural and regulatory genes of different HIV-1 subtypes and recent research suggests that the variability among HIV groups, subtypes and CRFs carry functional biological differences \[[@pone.0238027.ref012]\]. Subtypes have been shown in previous studies to be associated with disease progression \[[@pone.0238027.ref010]--[@pone.0238027.ref014]\] and mother-to-child transmission of HIV \[[@pone.0238027.ref015]\]. Reports on the impact of HIV subtypes on response to antiretroviral therapy vary; majority of studies which showed that subtypes have no effect on outcomes once on antiretroviral were either cross-sectional studies or longitudinal studies of 24 months or less \[[@pone.0238027.ref016]--[@pone.0238027.ref022]\]. However, Scherrer et al in a cohort study (1996--2009) reported an improved virologic outcome in white patients with non-B subtype particularly subtypes A and CRF02_AG compared to subtype B \[[@pone.0238027.ref021]\]. Resistance rates among children has been reported to be higher for non-B subtypes than for B subtypes; however, in the same study, subtypes were not associated with virologic response at 24 and 48 weeks after initiation of treatment \[[@pone.0238027.ref019]\]. While De Wit et al, reported no difference in the proportion of patients with viral loads below 400 copies/mL at month 24 post-initiation of ART, they found a significant difference in the median CD4+ T cell increase at month 24 when data from subtype B and non-subtype B infected patients were compared \[[@pone.0238027.ref018]\]. Mortality has also been reported to be associated with subtype D compared to other subtypes, though this finding may be confounded by socio-demographic factors \[[@pone.0238027.ref023], [@pone.0238027.ref024]\].

The majority of studies examining association of HIV-1 subtype with patient outcomes have largely focused on subtype B, the commonest variant in the USA and Western Europe and one that represents less than 15% of HIV-1 infections worldwide. Few studies have evaluated the effect of HIV subtypes for periods longer than 48 weeks and these were on ARV naïve HIV infected subjects \[[@pone.0238027.ref013], [@pone.0238027.ref024]--[@pone.0238027.ref026]\]. In this study, we examined the subtype distribution and the effect of these subtypes on disease outcome over a 5-year period in a cohort of patients receiving ART in a large teaching hospital location in southwest Nigeria.

Materials and methods {#sec006}
=====================

The study was an observational longitudinal study that took place in Lagos University Teaching Hospital (LUTH) at the HIV clinic, which provides care for over 8,000 HIV-positive patients. This study included all HIV-infected patients attending the APIN clinic of LUTH that were newly initiated on ART between September 2008 and June 2009, who provided informed consent, were above the age of 18 years, initiated on first-line ARV according to National guidelines and had subsequent clinical data \[[@pone.0238027.ref027]\]. The study was reviewed and approved by the Health Research and Ethical Committee of the Lagos University Teaching Hospital, the Institutional Review Board at the Harvard T. H. Chan, School of Public Health, the academic medical center of Amsterdam and the APIN Public Health Initiatives, Nigeria. HIV-2 positive patients and those with dual infections were excluded. The criteria for initiation of ART were the presence of a CD4+ cell count of \< 350 cells/μL or the presence of symptomatic HIV disease. Medical records from the electronic medical records developed by Harvard APIN program \[[@pone.0238027.ref028]\] were used to obtain demographic data (gender and age), clinical and laboratory data (ART regimen at ART initiation, CD4+ cell counts and viral load values). Data for serial CD4 count and viral loads were extracted from electronic data base at baseline, then 3 monthly for the first year, subsequently every 12 months till the 60^th^ month. This made a total of nine data points (baseline, 3-months, 6-months, 9-months, 12-months, 24-months, 36-months, 48-months and 60-months), ([S1 Fig](#pone.0238027.s001){ref-type="supplementary-material"}). Data for HIV sub-types was a secondary data obtained from the PASER-M study, which assessed the prevalence of primary resistance in 6 African countries after ART roll-out. One of the secondary objective of the study was to determine the relationship between HIV subtypes and ART drug resistance. The PASER-M original study design was a prospective cohort study. Its sample size was estimated at a minimum of 190 individuals per site based on virologic outcome after 24 months on ART, 20% loss to follow up and a 25% mortality rate after 24 months \[[@pone.0238027.ref029], [@pone.0238027.ref030]\]. In the LUTH site, an initial 240 patients were recruited, 198 participants had baseline sequence data. Of these, only 169 participants had subsequent clinical data and hence were included in this present study. At baseline, five mls of blood was drawn into EDTA bottles for genetic analysis. Cryopreserved plasma samples obtained before initiation of therapy were shipped on dry ice to University of Witwatersrand, South Africa for sequence analysis in 3 batches. The South African laboratory used the NucliSens EasyQ real-time Assay version 2.0 (bio-Merieux, Lyon, France) for reference HIV RNA determination. For samples with viral load \>1000RNA copies/mL, the whole of the protease gene and codons 1--300 of reverse transcriptase gene were sequenced. The Laboratory used an in-house sequencing method with an ABI Prism 3730 Genetic analyzer (Applied Biosystems, Foster City CA) \[[@pone.0238027.ref030], [@pone.0238027.ref031]\]. Subtypes were determined using the REGA HIV-1 subtyping algorithm version 2.0 \[[@pone.0238027.ref032]\]. Additional STAR genotype analysis was carried out when required \[[@pone.0238027.ref033]\].

A favorable immunologic response was defined as CD4+ cell count rise of ≥100 copies/μL from baseline CD4+ cell count within 12 months, or CD4+ cell count ≥350cells/μL at end of study period. Virologic failure was defined as two consecutive HIV RNA levels \>1000copies/mL following viral suppression and at least 6 months on ART. Viral suppression was defined as HIV RNA levels ≤1000 copies/mL. Viral rebound was defined as VL\>1,000copies/mL following suppression.

All statistical analyses were conducted using SPSS version 21. Baseline VL and CD4+ cell counts were compared between HIV subtypes using the Kruskal-Wallis test. Proportions with an increase in CD4+ cell of \> 100 cells/μL within first 12 months of initiation of ART and virologic rebound/failure were compared across subtypes using the Chi-squared test. Kaplan-Meier curves were used to examine time to CD4+ count rise to ≥350 cells/μL and VL≤1000 copies/mL after initiation of ART across subtypes, with the log-rank test being used to test the significance of observed differences between groups. Survival curves were drawn using GraphPad Prism version 8.4.3 (686). Median CD4+ cell rise overtime was also determined and presented as a graph.

Results {#sec007}
=======

One hundred and sixty-nine HIV-infected patients who gave consent and were newly initiated on ART as per National guidelines were included in this evaluation. They were followed for up to five years post-initiation of ART. The majority (64.3%) of participants were females and male: female ratio was comparable across subtypes. "[Table 1](#pone.0238027.t001){ref-type="table"}"

10.1371/journal.pone.0238027.t001

###### Baseline demographics and clinical characteristics of the study population by subtypes.

![](pone.0238027.t001){#pone.0238027.t001g}

                                                               HIV subtype N (%)                                                                                                        
  ------------------------------------------------------------ ------------------- ------------------- ------------------- -------------------- ------------------- ------------------- ------
  **Sex**                                                                                                                                                                               
  Male                                                         11 (27.5)           37 (39.8)           8 (50.0)            2 (18.2)             3 (33.3)            61 (36.1)           0.32
  Female                                                       29 (72.5)           56 (60.2)           8 (50.0)            9 (81.8)             6 (66.7)            108 (63.9)          
  **Median Age**(years)                                        34 (30--38)         35 (32--43)         38 (35--46)         35 (33--41)          43 (35--48)         35 (32--42.5)       0.05
  **Median CD+4 cells/μL(IQR**)                                128 (62.0--185.8)   127 (64.0--198.0)   146 (81.3--202.3)   144 (121.8--211.0)   116 (93.5--187.5)   131 (66.3--194)     0.81
  **Median VL Log copies/mL(IQR)**                             5.24 (4.89--5.60)   4.87 (4.09--5.48)   5.27 (4.28--5.64)   4.91 (3.40--5.75)    5.47 (5.02--5.86)   5.06 (4.29--5.59)   0.16
  **ARV at initiation**[\*](#t001fn002){ref-type="table-fn"}                                                                                                                            
  AZT/3TC                                                      24 (60)             54 (58.0)           12 (75)             6 (54.5)             7 (77.8)            103 (60.9)          
  TDF/FTC                                                      14 (35)             31 (33.3)           2 (12.5)            3 (27.3)             2 (22.2)            52 (30.8)           
  ABC/3TC                                                      2 (5)               6 (6.5)             2 (12.5)            1 (9.1)              0 (0)               11 (6.5)            
  D4T/3TC                                                      0 (0)               2 (2.2)             0 (0)               1 (9.1)              0 (0)               3 (1.8)             

IQR-interquartile range, AZT-Zidovudine, 3TC-Lamivudine, TDF- Tenovofir, D4T-Stavudine.

\*ARV are classified based on NRTI backbone.

The median age of participants was 35 years with majority (69.8%) being below the age of 40 years. The baseline CD4+ cell count and viral load did not statistically differ between subtypes (P\>0.05). "[Table 1](#pone.0238027.t001){ref-type="table"}" One hundred and three (60.9%) of participants were on AZT/3TC based regimen and 52 (38%) on TDF/FTC based regimens. "[Table 1](#pone.0238027.t001){ref-type="table"}" The third drug in the ARV regimen was Nevirapine in 139 (82.2%), Efavirenz in 29 (17.2%) and Saquinavir/Ritonavir in 1 (0.6%) of participants

A complex HIV-1 diversity was seen, with multiple subtypes (D, G, J, K) and CRFs (02_AG, 01_AE, 03_AB, 14_BG, 06_cpx, 18_cpx, 36_cpx, 43_02G). The most common variants were CRF 02_AG (55.03%) and G (23.67%). "[Table 1](#pone.0238027.t001){ref-type="table"}" CRF06_cpx and CRF18_cpx accounted for 9.47% and 6.51% respectively. The remaining variants accounted for only 5.33% of the sequence diversity. These was made up of subtypes D (1.18%), J (0.59%), K (0.59%), CRF01_AE (0.59%), CRF03_AB (0.59%), CRF14_BG (0.59%), CRF36_cpx (0.59%), and CRF43_02G (0.59%). "[Table 1](#pone.0238027.t001){ref-type="table"}"

At 12 months' post-initiation of ART, the proportion of participants who achieved favourable immunologic response was comparable across subtypes "[Table 2](#pone.0238027.t002){ref-type="table"}".

10.1371/journal.pone.0238027.t002

###### Proportion with favorable immunologic response (CD4+ cell count rise of ≥100 copies/μL from baseline) at 12 months after initiation of ARV drugs.

![](pone.0238027.t002){#pone.0238027.t002g}

                                           HIV subtypes n (%)                                                
  ---------------------------------------- -------------------- ----------- ----------- ---------- --------- ------------
  **CD 4+ cell count rise at 12 months**                                                                     
      ≥100 cells/μL                        59 (91.7)            59 (96.7)   11 (91.7)   10 (100)   8 (100)   110 (97.6)
  \< 100 cells/μL                          2 (8.3)              2 (3.3)     1 (8.3)     0 (0)      0 (0)     5 (4.3)

P\>0.05.

The proportion that achieved an virologic suppression at month 3, 6 and 12 post-initiation of ART were also comparable among the different subtype populations. "[Table 3](#pone.0238027.t003){ref-type="table"}"

10.1371/journal.pone.0238027.t003

###### Proportion with viral suppression (VL ≤1000 copies/mL)at 3 months, 6 months and 12 months after initiation of ARV drugs.

![](pone.0238027.t003){#pone.0238027.t003g}

                                    G           02_AG       06_cpx     18_cpx     Others     Total
  --------------------------------- ----------- ----------- ---------- ---------- ---------- -----------
  **VL at 3 months (copies/mL)**                                                             
      \>1000                        2 (8.7)     11 (25.6)   2 (25.0)   2 (40.0)   1 (14.3)   18 (20.9)
      ≤ 1000                        21 (91.3)   32 (74.4)   6 (75.0)   3 (60.0)   6 (85.7)   68 (79.1)
  **VL at 6 months (copies/mL)**                                                             
      \>1000                        3 (17.6)    8 (18.2)    1 (11.1)   1 (16.7)   2 (28.6)   15 (18.1)
  ≤ 1000                            14 (82.4)   36 (81.8)   8 (88.9)   5 (83.3)   5 (71.4)   68 (81.9)
  **VL at 12 months (copies/mL)**                                                            
      \>1000                        3 (13.0)    9 (15.8)    3 (27.3)   1 (10.0)   2 (25.0)   18 (16.5)
      ≤ 1000                        20 (87.0)   48 (84.2)   8 (72.7)   9 (90.0)   6 (75.0)   91 (83.5)

P\>0.05.

All subtypes showed a steady rise in CD4 + cell count; however, CFR06_cpx and CRF18_cpx demonstrated frequent peaks and dips. In both these subtypes, a more detailed scrutiny of data revealed that both had one participant with inconsistently high CD4 counts which corresponded to the peaks in the graph. The few number of participant in both populations made the effect of this "outliers" marked. "[Fig 1](#pone.0238027.g001){ref-type="fig"}".

![Median CD4+ cell count rise over time across subtypes.](pone.0238027.g001){#pone.0238027.g001}

At the end of the observation period, there were no significant differences in proportion of patients with viral suppression or with CD4 counts≥350cells/μL. "[Table 4](#pone.0238027.t004){ref-type="table"}".

10.1371/journal.pone.0238027.t004

###### Outcome at 60th months of follow-up of each patient from time of initiation of ARV.

![](pone.0238027.t004){#pone.0238027.t004g}

                                                              HIV subtypes n (%)                                                 
  ----------------------------------------------------------- -------------------- ----------- ----------- ----------- --------- ------------
  Status in care[\*](#t004fn001){ref-type="table-fn"}                                                                            
      Still in care                                           26 (65.0)            53 (57.0)   13 (81.3)   10 (90.9)   9(100)    111 (65.7)
      LTFU                                                    13 (32.5)            38 (40.8)   2 (12.5)    1 (9.1)     0 (0)     54 (32.0))
      Dead                                                    0 (0)                1 (1.1)     1 (6.3)     0 (0)       0 (0)     2 (1.2)
      Transferred to other facilities                         1 (2.5)              1 (1.1)     0 (0)       0 (0)       0 (0)     2 (1.2)
  Immunologic status[\*\*](#t004fn002){ref-type="table-fn"}                                                                      
  Median CD4+(cells/μL)                                                                                                          
      \< 350                                                  3 (30)               3 (20.8)    2 (40)      1 (33.3)    1 (25)    12(26.1)
      ≥ 350                                                   7 (70)               19 (79.2)   3 (60)      2 (66.7)    3 (75)    34 (73.9)
  Virologic status[\*\*](#t004fn002){ref-type="table-fn"}                                                                        
  Median VL (copies/mL)                                                                                                          
      \< 1000                                                 2 (66.7)             12 (92.3)   5 (100)     0 (0)       1 (100)   20 (90.9)
      ≥ 1000                                                  1 (33.3)             1 (7.7)     0 (0)       0 (0)       0 (0)     2 (9.1)

\*P value (likelihood ratio) = 0.046.

\*\*P \>0.05. Only 46 (41.4%) and 22 (19.8%) of those still in care had CD4 + cell count or VL respectively done at the 60^th^ month.

The median time to attaining CD4+ cell count increase of ≥350cells/μL was 24 months (IQR: 6--48 months). The shortest median time to CD4+ cell count increase of ≥350cells/μL was observed in CRF 06_cpx-infected population (12 months; 95% confidence interval \[CI\]: 0.00--44.93 months) compared to CRF 18_cpx (24 months; 95% CI, 9.80--38.20 months), CRF 02_AG (24 months; 95% CI: 18.77--29.23 months) and subtype G (36 months; 95% CI: 22.90--49.10 months). However, this differences in median time to a rise in CD4+ cell count of ≥350cells/μL were not statistically significant. (p\>0.05) No significant difference in the survival curves for the different subtype population was observed, P\>0.05 "[Fig 2](#pone.0238027.g002){ref-type="fig"}".

![Kaplan_Meier analysis of time to reach CD4+ T_cell count of≥350 cells/μL on cART (A) Comparing the all subtypes. (B) Comparing subtypes G and CRF02_AG.](pone.0238027.g002){#pone.0238027.g002}

The baseline VL was comparable across the different subtype populations "[Table 1](#pone.0238027.t001){ref-type="table"}". Eight of 15 (53.3%) of subjects with CRF 06_cpx had virologic rebound during the study. This was significantly higher than those with virologic rebound among subjects with subtype G, 11/18 (37.9%) and subtype 18_cpx, 2/ 8 (20%). P \<0.05. However, there was no statistically significant difference in the proportion who had virologic failure during the study period. Overall, 8 (6.1%) of study population had a virologic failure. "[Table 5](#pone.0238027.t005){ref-type="table"}".

10.1371/journal.pone.0238027.t005

###### Proportion with virologic rebound or virologic failure during the study period.

![](pone.0238027.t005){#pone.0238027.t005g}

                                                             HIV subtypes n (%)                                                  
  ---------------------------------------------------------- -------------------- ----------- ------------ ---------- ---------- ------------
  Virologic rebound[\*](#t005fn001){ref-type="table-fn"}                                                                         
      No                                                     18 (62.1)            56 (81.2)   7 (46.7)     8 (80.0)   5 (55.6)   94 (71.2)
      Yes                                                    11 (37.9)            13 (18.8)   8 (53.3)     2 (20.0)   4 (44.4)   38 (28.8)
  Virologic Failure[\*\*](#t005fn002){ref-type="table-fn"}                                                                       
      No                                                     28 (100.0)           63 (91.3)   15 (100.0)   9 (90.0)   8 (88.9)   123 (93.9)
      Yes                                                    0 (0)                6 (8.7)     0 (0)        1 (10.0)   1 (11.1)   8 (6.1)

\*P = 0.035.

\*\*P\>0.05 Virologic failure was defined as two consecutive HIV RNA levels \>1000copies/mL following viral suppression and at least 6 months on ART. Viral rebound was defined as VL\>1,000copies/mL following suppression.

The shortest median time to VL ≤ 1,000 copies/mL were observed in Subtype G infected population (3months; 95% confidence interval \[CI\], 2.22--3.78 months). Other major subtypes had a median time of 6 months to VL ≤ 1,000 copies/mL with CI as follows; CRF 06_cpx (3.99--8.01 months), CRF 18_cpx (1.48--10.52 months) and CRF 02_AG (4.91--7.09 months). The overall median time to VL ≤1,000 copies/mL for the study population was 3 months (CI, 2.20--3.81 months). However, there was no significant difference in the survival curves for the different subtype populations as P\>0.05. "[Fig 3](#pone.0238027.g003){ref-type="fig"}"

![Kaplan-Meier analysis of time to reach viral load of ≤ 1000 copies /mL on cART.](pone.0238027.g003){#pone.0238027.g003}

A hundred and eleven (65.7%) participants were still in care, 54 (34%) were lost to follow up, 2 (1.2%) had died, and 2 (1.2%) had been transferred to another facility "[Table 4](#pone.0238027.t004){ref-type="table"}". Participants with CRF 06_cpx and CRF 18_cpx had a significantly greater proportion still in care compared to the other subtypes. P\<0.05 "[Table 4](#pone.0238027.t004){ref-type="table"}".

Discussion {#sec008}
==========

In this evaluation of HIV-1 genetic diversity in southwest Nigeria, we found the most common variants to be CRF02_AG and subtype G, which is similar to what previous studies examining genetic diversity in Nigeria have found \[[@pone.0238027.ref007], [@pone.0238027.ref008], [@pone.0238027.ref010], [@pone.0238027.ref011], [@pone.0238027.ref034]\] The dominant spread of CRF02_AG in West Africa has been attributed to the replicative fitness it confers over subtype A and G in the same geographical region \[[@pone.0238027.ref035]\]. The other subtypes, including D, J, K, CRF43_02G, CRF06_cpx and CRF36_cpx, which were also found in this study have also been reported in other West African settings, largely at a lower prevalence \[[@pone.0238027.ref036]\]. Reported prevalence of CRF06_cpx in Nigeria vary between 4.4% and 11% \[[@pone.0238027.ref008], [@pone.0238027.ref037]\]. in this study its prevalence was 9.5%. The prevalence of CRF43_02G has been reported as higher in Abuja (18.5%) than what we found in Lagos (0.59%) \[[@pone.0238027.ref038]\]. CRF14_BG and CRF03_AB, which have not previously been reported in Nigeria account for 0.59% each of subtypes report in this study. ‬‬‬‬‬‬‬‬‬‬‬‬‬

To date, most reports of associations between subtypes and immunologic outcomes have focused on comparing patients infected with subtype B to those with non-subtype B viruses. As such, different studies lump different subtypes as non-subtype B, making it difficult to know the impact of less predominant subtypes. Subtype B is uncommon in Nigeria. In this study, baseline CD4+ cell count and proportion who achieved favourable immunologic responses at 12 months were comparable across subtypes "Tables [1](#pone.0238027.t001){ref-type="table"}--[3](#pone.0238027.t003){ref-type="table"}", similar to other studies \[[@pone.0238027.ref039], [@pone.0238027.ref040]\]. It must be noted that in a study by Geretti et al, the authors reported higher baseline CD4+ cell counts in subtype B infected patients as compared to other patients that were maintained throughout the 39 weeks duration of study \[[@pone.0238027.ref041]\].

A study in Malaysia reported a shorter median time for CD4+ T-cell count increase to 350 cells/μL for CRF01_AE compared to subtype B-infected patients \[[@pone.0238027.ref039]\]. However, in two studies from China, where the CRF01_AE accounts for 50--60% of HIV-1 subtypes, CRF01_AE subtype was correlated with a significant risk of accelerated HIV/AIDS progression compared to non-CRF01_AE subtypes \[[@pone.0238027.ref040]--[@pone.0238027.ref042]\]. Similar rates of CD4+ cell count recovery for all subtypes as documented in this study has been reported in several other studies \[[@pone.0238027.ref040], [@pone.0238027.ref041], [@pone.0238027.ref043]\]. However, a study in France by Chaix M et al showed that patients infected with a non-B virus including CRF02_AG, had better immunological responses between the first 18 months than those infected with a subtype-B virus \[[@pone.0238027.ref044]\]. In our study, sub-analysis comparing immunologic response in subtypes- CFR02_AG and other subtypes did not show a significant difference in proportion who achieved a rise in CD4+ cell count of ≥100 cells/μL at 12 months or who had a rise of ≥ 350 cells/μL at 60 months.

Though the shortest median time to VL ≤1,000 copies/mL was observed in the subtype G infected population, overall virologic outcomes were comparable across subtypes. Similar findings have been reported in several other studies \[[@pone.0238027.ref019], [@pone.0238027.ref041], [@pone.0238027.ref043]--[@pone.0238027.ref046]\].

Data quality is highly dependent on the completeness of clinical and laboratory values. As expected of cohort studies, this study being an observational programme study had some missing laboratory data which increased as study continued over time. At the end of the study period of this present analysis, the percentage loss to follow-up was 32.0% ([Table 4](#pone.0238027.t004){ref-type="table"}). Another limitation of this study is the fact that the data on HIV subtypes was a secondary data of all available complete data as sample size was not previously calculated. The fact that VL was not assessed at all points for all patients creates the possibility of potential bias. Being an observational study, estimates on time to virologic suppression are also based only on patients with available data, so not all patients can be assessed at all time points. However, the long follow up period and the within-program comparison of subtypes which limits expected confounders are the strengths of this study.

Conclusion {#sec009}
==========

In conclusion, we found no evidence of an association between subtype and immunologic or virologic response to therapy, suggesting that current antiretroviral agents that are broadly in use have similar efficacy across subtypes that predominate in southwest Nigeria. The high number of HIV-1 subtypes and recombinant viruses observed in this study confirms that continuous molecular and virologic monitoring of HIV-1 in Nigeria remains of great importance.

Supporting information {#sec010}
======================

###### Study profile showing number of participants included in analysis at each time line.

(DOCX)
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Click here for additional data file.
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1.    Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified whether consent was written or verbal/oral. If consent was verbal/oral, please specify: 1) whether the ethics committee approved the verbal/oral consent procedure, 2) why written consent could not be obtained, and 3) how verbal/oral consent was recorded. If your study included minors, please state whether you obtained consent from parents or guardians in these cases.

3\. Please amend either the title on the online submission form (via Edit Submission) or the title in the manuscript so that they are identical.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This study is of great significance in the field of HIV treatment and monitoring of circulating subtypes, the results can be used for clinical purposes and for the treatment and care of those infected with HIV. It is also important to note the differences in subtypes circulating in developing countries such as USA and Europe with those obtained in Africa where the HIV pandemic hit the hardest. The study was well written and the author showed understanding of the subject and the methodology used was suited to this study. However, there were some issues with the reporting of the results. It was not easy to follow. This is understandable as they needed to summarize 5 years of work in a short manuscript.

• Minor issues:

1\. Methods: The time points need to be mentioned here and this will help with the reporting of the time line in the results section. There is also no mention of how many samples were shipped to Johannesburg for testing by each time point. Page 5

2\. Results:

o The results were very confusing to follow and understand, but this should be sorted once the time points are clearly stated in the methods section. I suggest that flow diagram showing sample availability at each of the tested time points be included and reasons for samples missing and those with missing data (Page 7). For example, in Table 3 the researchers list possible reasons why samples are missing but even in those that were still under care, the numbers reported don't add up to the totals in the table (Page 9).

o Separate reporting of results for viral load and CD4 counts it will be clearer when reporting in the results section. Also report them by time points so that it is clear to see the rise in CD4 or viral load by time point tested. (Page 9 and 10)

o There also needs to be consistency in the number of visits, in Figure 1 there are 9 time points for CD4 count while Table 2 and 3 show that you had 2 visits (Page 8 and 9). For viral load there are 4 visits as shown in Table 2 and Table 3 (Page 8 and Page 9).

3\. Discussion: there is inconsistencies in the CD4 counts of those infected with CRF 06-cpx and CRF 18-cpx subtypes (Figure 1). The authors did not show why this was happening and this happened for just these two subtype. The low numbers that they mentioned in the results section does not explain such (Page 9).

Minor issues:

1\. Reference \#14 is not in the text but is stated in the reference list.

Reviewer \#2: In this manuscript, Ogbenna and colleagues longitudinally followed up 169 study participants infected with different subtypes who were started on antiretroviral therapy in Nigeria. The authors report that the individuals did not differ in baseline CD4+ T cell counts or viral loads according to HIV-1 subtype, and there were no differences in immunological and virological outcomes following initiation of antiretroviral therapy. Overall, this is a sound study although I found the report generally poorly written and sometimes confusing.

1\) Do the authors have CD4% and CD4:CD8 ratios for participants in the cohort? Others have reported that CD4% and CD4:CD8 ratios do not normalize even after long-term antiretroviral therapy in other cohorts so it would be interesting to see whether that holds true for this cohort and if there are differences in these measures by HIV-1 subtype.

2\) In table 1, only two antiretroviral drugs are shown for participants in different categories. Were participants in this cohort on two-drug regimens instead of three? Why is that the case?

3\) In all the tables, there is repetition in data presentation- why for example show the numbers of both males and females? Why not just show one category (with percentage) since for these binary variables it is obvious what the numbers and percentages will be for the other category? The same applies for measures such as CD4+ T cell count increases above 100 cells/µl, viral load suppression below 1,000 copies/ml, etc.

4\) The authors should show the confidence intervals for the data presented in figures 1-3. Also is this the same data in tables 1-4 and only presented differently? It would be preferable that there is no data repetition unless there is a specific separate point that the authors want to highlight by presenting the same data in different formats.

5\) The figure legends for figures 1 to 3 are mixed up with the manuscript results narrative. The figure legends should be separated from the results narrative to make it easier to follow.

6\) Although the REGA tool was used for subtyping, a more robust phylogenetic analysis with reference sequences would have been useful, particularly considering the extreme diversity of viral strains in Nigeria.

7\) The conclusion that a higher proportion of CRF-06-cpx and CRF-18-cpx remained in care at 60 months seems tenuous and implies that there are differences between subtypes in terms of response to treatment. Unless the authors can show that this is a solid finding backed by systematic data rather than a chance finding, it should be removed from the abstract.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

18 Jun 2020

Academic Reviewer:

t is unclear if the 169 participants included represent all patients at this hospital that met the enrollment criteria or a subset of those individuals. How representative are these 169 individuals of the HIV-positive population at this hospital? In Nigeria?

Response: 240 adult patients aged \>18 years were recruited over a period of one year. Of these, 198 participants had a baseline sequence data out of which only 169 had clinical follow up data to interrogate the impact of subtypes on treatment outcomes.

A detailed flow chart has been included as supplementary data.

(Page 5,Lines 6, 108; Page 6, )116-127

A more robust discussion of the potential limitations is warranted.

Response:

In line with the Editor's review, we have revised and elaborated on the limitations of the study. (Page 14, Lines 249-253)

The authors should who the sequence data as a phylogenetic tree.

Response:

This present study is a secondary data analysis. We have now described the primary study in the methodology section. Reference of the primary study was also included. (Page 6, Line 119-125)

How do the authors know that a sufficient sample size was included to robustly evaluate if subtypes differ in disease progression?

Response:This was a programme study and baseline sequence data was conducted for the participants. Our study is a secondary data analysis of all available complete data. Though the primary study for the sequence data was a prospective cohort study and appropriate sample size was calculated based on: virologic outcomes after 24 months on ART, a 20% loss to follow up and a 25% mortality rate after 24month. The fact that sample size was not calculated initially to include a 5-year follow up remains a limitation of the study. This has been alluded to in page 14, line 252-259.

Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified whether consent was written or verbal/oral. If consent was verbal/oral, please specify: 1) whether the ethics committee approved the verbal/oral consent procedure, 2) why written consent could not be obtained, and 3) how verbal/oral consent was recorded. If your study included minors, please state whether you obtained consent from parents or guardians in these cases.

Response: A written consent was obtained for all participants.

Reviewer 1

Methods: The time points need to be mentioned here and this will help with the reporting of the time line in the results section. There is also no mention of how many samples were shipped to Johannesburg for testing by each time point. Page 5

Response:Data for serial CD4 count and viral loads were extracted from electronic data base at baseline, 3/12, 6/12, 9/12, 12 months, 24 months, 36months, 48 months and 60month. This has been reflected in the manuscript

Samples were shipped in 3 batches. This also has been reflected in the methodology(Page 6, Lines 116-119)

2\. Results:

o The results were very confusing to follow and understand, but this should be sorted once the time points are clearly stated in the methods section. I suggest that flow diagram showing sample availability at each of the tested time points be included and reasons for samples missing and those with missing data (Page 7). For example, in Table 3 the researchers list possible reasons why samples are missing but even in those that were still under care, the numbers reported don't add up to the totals in the table (Page 9).

o Separate reporting of results for viral load and CD4 counts it will be clearer when reporting in the results section. Also report them by time points so that it is clear to see the rise in CD4 or viral load by time point tested. (Page 9 and 10)

o There also needs to be consistency in the number of visits, in Figure 1 there are 9 time points for CD4 count while Table 2 and 3 show that you had 2 visits (Page 8 and 9). For viral load there are 4 visits as shown in Table 2 and Table 3 (Page 8 and Page 9).

Response:Time points have been stated in methodology andFlow chart added as a supplementary data.

Data on those still in care was obtained from drug pick up data. However, it was not possible to determine why these patients had missing laboratory results as such records are not kept in the clinic.

Table 2 has been separated for VL and CD+ count and reported by timelines. A favorable immunologic response was defined as CD4+ cell count rise of ≥100 copies/µL from baseline CD4+ cell count within 12 months, hence table 2a shows this. Viral suppression was defined as HIV RNA levels ≤ 1000 copies/mL. This is reflected in table 2b and the title has been changed to reflect the content. (Page 8 and 9)

Table 2, shows as title reflects, outcome at first 12 months hence the fewer number of visits, while figure 1 shows outcome over the whole period of study hence 9 time points.

Table 3, as title reflects shows outcome at end point only i.e. month 60

3\. Discussion: there is inconsistencies in the CD4 counts of those infected with CRF 06-cpx and CRF 18-cpx subtypes (Figure 1). The authors did not show why this was happening and this happened for just these two subtype. The low numbers that they mentioned in the results section does not explain such (Page 9).

Response:In line with the Reviewer's comment, we have revised and elaborated on probable reasons. (Page 9 Line 176-179)

Minor issues:

1\. Reference \#14 is not in the text but is stated in the reference list.

Response: This has been corrected in Page 4 line 84.

Reviewer 2:

Do the authors have CD4% and CD4:CD8 ratios for participants in the cohort? Others have reported that CD4% and CD4:CD8 ratios do not normalize even after long-term antiretroviral therapy in other cohorts so it would be interesting to see whether that holds true for this cohort and if there are differences in these measures by HIV-1 subtype.

Response: No, we do not have CD % or CD4: CD8 ratio.

2\) In table 1, only two antiretroviral drugs are shown for participants in different categories. Were participants in this cohort on two-drug regimens instead of three? Why is that the case?

Response:No they were on 3 drugs. however, they were classified based on NRTI backbone. (Page 6, Line 156)

3\) In all the tables, there is repetition in data presentation- why for example show the numbers of both males and females? Why not just show one category (with percentage) since for these binary variables it is obvious what the numbers and percentages will be for the other category? The same applies for measures such as CD4+ T cell count increases above 100 cells/µl, viral load suppression below 1,000 copies/ml, etc.

Response: There is no repetition of data. Table titles have been edited to represent content. (Table 2a: Page 8;Table 2b: Page 9)

4\) The authors should show the confidence intervals for the data presented in figures 1-3. Also is this the same data in tables 1-4 and only presented differently? It would be preferable that there is no data repetition unless there is a specific separate point that the authors want to highlight by presenting the same data in different formats.

Response: This is not the same data.Figure 1 shows the median CD4+ cell count over the whole period of study. Table 2a show proportion with a favourable immunologic response at 12 months after initiation of therapy, while table 2b shows proportion with viral suppression at variable times within the first 12 months. Table 3 shows outcome at end of study period which is 60th month. Confidence Intervals were reported as prose page 10, 176-182.

5\) The figure legends for figures 1 to 3 are mixed up with the manuscript results narrative. The figure legends should be separated from the results narrative to make it easier to follow.

Response: This has been rectified. (Page 8, line 169)

The Journal requires that figure legend be placed at place where it first mentioned in article, though it is uploaded separately.

6\) Although the REGA tool was used for subtyping, a more robust phylogenetic analysis with reference sequences would have been useful, particularly considering the extreme diversity of viral strains in Nigeria.

Response: As explained above, the data sequence data was a secondary data. This has been stated and referenced in the methodology.

7\) The conclusion that a higher proportion of CRF-06-cpx and CRF-18-cpx remained in care at 60 months seems tenuous and implies that there are differences between subtypes in terms of response to treatment. Unless the authors can show that this is a solid finding backed by systematic data rather than a chance finding, it should be removed from the abstract.

Response: This has been removed from the abstract. (Page 2, Lines 44 & 45)
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9 Jul 2020

PONE-D-19-29623R1

The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos university teaching hospital: A longitudinal evaluation

PLOS ONE

Dear Dr. Ogbenna,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please make the minor updates requested by Reviewer \#2 prior to acceptance of your manuscript.

Please submit your revised manuscript by Aug 23 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Jason Blackard, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Please make the minor updates requested by Reviewer \#2 prior to acceptance of your manuscript.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: In this version of the manuscript, Ogbenna and colleagues have addressed most of the concerns from reviewers. I have a few minor issues that the authors should address.

1\) The authors state that antiretroviral drug categories shown are classified based on the NRTI backbone. I think it is still important to indicate what the third drug used was even if it was not uniform across all participant groups.

2\) I understand that the confidence intervals for the data shown in figures 1-3 are described in the narrative. Why are they not shown in the figures?

3\) The supplementary figure shown indicated that there were 169 study participants, 86 with viral load and 88 without viral load. These numbers should be checked as they do not add up to 169.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1
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Reviewer 2

Thank you Sir/Ma for the time, care and effort you have put into reviewing this manuscript. We are grateful for your generous comments.

We gave gone over all the points raised and addressed them. We thank you for pointing out the need to indicate the third ARV used by participants. This has been addressed in result section; page 8, line 160-161.

We have also reflected the confidence intervals in the graph for figures 1-3 as suggested.

We thank you for spotting the discrepancy in the supplementary figure. This was a typo error; 86 had viral loads and 83 (not 88) did not have viral loads. This correction has been effected in the supplementary figure.

We say thank you for your inputs.

Regards

Editor,

Thank you Sir for your time and efforts. We have addressed the reviewers questions.

We have also uploaded the figures into PACE and figures that meet the PLOS ONE requirements have been uploaded.

We have also uploaded a tracked and clean copy of the manuscript

Thank you Sir in advance for your continuous support.

Best regards
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The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos university teaching hospital: A longitudinal evaluation

PONE-D-19-29623R2

Dear Dr. Ogbenna,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Jason Blackard, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

None

Reviewers\' comments:

None
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14 Aug 2020

PONE-D-19-29623R2

The Impact of HIV-1 Subtypes on Virologic and Immunologic Treatment Outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation

Dear Dr. Ogbenna:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jason Blackard

Academic Editor

PLOS ONE
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